TITLE

Clinical Trial Status Differentiates Biotechs

AUTHOR(S)
Santini, Laura
PUB. DATE
February 2004
SOURCE
Investment Dealers' Digest;2/23/2004, Vol. 70 Issue 8, p11
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Discusses how the status of clinical trials affects the share price of biotech companies after going public. Success of the initial public offering (IPO) of Eyetech Pharmaceuticals Inc.; Contrast with the IPO of GTx Inc.; Rethinking among investment bankers in the wake of contrasting results.
ACCESSION #
12341797

 

Related Articles

  • GTx Offering to Add $40M, Rebuild Reserves, Buy Time. Wall, Tom // BioWorld Today;10/28/2010, Vol. 21 Issue 209, p1 

    This article focuses on the public offering issued by GTx Inc. to raise 40 million U.S. dollars and rebuild declining cash reserves. There is a plan by GTx to sell 14.3 million shares of common stock at 2.80 U.S. dollars per share. A 30-day option was granted by GTx to Lazard Capital Markets LLC...

  • Financings Roundup.  // BioWorld Today;10/25/2007, Vol. 18 Issue 208, p6 

    The article announces the initial public offering of ARYx Therapeutics in October 2007. As reported, ARYx plans to offer 5 million shares, amounting to between $14 and $16 per share. The proceeds will be used to support the company's clinical trials to reformulate existing drugs. The lead...

  • Pharmasset Prices IPO Lower Than Expected To Raise $45M. Boggs, Jennifer // BioWorld Today;4/30/2007, Vol. 18 Issue 83, p1 

    The article reports that Pharmasset Inc. has set a $9 per share price for its initial public offering (IPO). The company aims to raise $45 million from the IPO. Previously, the company priced its shares between $12 and $14, but reduced it to $9 in relation to the Phase II program for clevudine....

  • Dyax Raising $38.5 Million To Fund Its DX-88 Trials. Morrison, Trista // BioWorld Today;7/16/2007, Vol. 18 Issue 136, p1 

    The article reports that Dyax Corp. has decided to raise funds via a public offering deal. Information regarding the decision's impact on the stock price trading of the firm is discussed. It also discusses the size of the offering and the status of the firm's clinical trial with DX-88 in...

  • Merrimack Pharmaceuticals Aims to Raise $100M in IPO. Shaffer, Catherine // BioWorld Today;3/30/2012, Vol. 23 Issue 62, p1 

    The article reports on the pricing by Merrimack Pharmaceuticals Inc. of an initial public offering (IPO) of 14.3 million shares of common stock at seven U.S. dollars per share. During the first day of trading, Merrimack stocks dropped by 96 cents and settled at 6.04 U.S. dollars. There is a plan...

  • Pluristem Raising $32M Publicly As PLX Pipeline Gains Attention. Boggs, Jennifer // BioWorld Today;9/17/2012, Vol. 23 Issue 180, p1 

    The article reports on the move of Pluristem Therapeutics to nearly double its cash position with a public offering in 2012. The Israeli company aims to raise 32 million U.S. dollars from the public offering by selling eight million units. The news lead to a decline in the price of the company's...

  • Insmed Prices $26M Offering Focusing on CF lung infections. Winter, Peter // BioWorld Today;10/1/2012, Vol. 23 Issue 190, p1 

    The article reports on the pricing by Insmed Inc. of a 26 million U.S. dollar direct public offering of 6.3 million shares of its common stock. By October 31, 2012, Insmed intends to close the deal which will also offer additional shares of its common stock up to two million U.S. dollars....

  • Exact raises $64.7 million in common stock offering. FORD, OMAR // Medical Device Daily;11/11/2010, Vol. 14 Issue 220, p1 

    The article reports on Exact Sciences' completion of its underwritten public offering of common stock. The transaction, priced at 6 U.S. dollars per share, sold a total of 11,500,000 shares of common stock due to the exercise in full of the overallotment option. This amounted to approximately 69...

  • Chelsea Follows Phase III Success with Public Offering. Shaffer, Catherine // BioWorld Today;10/4/2010, Vol. 21 Issue 191, p1 

    The article reports that Chelsea Therapeutics International Ltd. launched a public offering which could give the company approximately 32.8 million U.S. dollars in net proceeds. Chelsea Therapeutics priced its shares of common stock at 4.90 per share for the public offering. According to the...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics